DexCom (DexCom) Debt-to-Asset

: 0.41 (As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

DexCom's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $21 Mil. DexCom's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $2,573 Mil. DexCom's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was $6,265 Mil. DexCom's debt to asset for the quarter that ended in Dec. 2023 was 0.41.

DexCom Debt-to-Asset Historical Data

The historical data trend for DexCom's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DexCom Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.48

0.43

0.44

0.40

0.41

DexCom Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial															0.40	0.39	0.49	0.41	0.41

Competitive Comparison

For the Medical Devices subindustry, DexCom's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DexCom Debt-to-Asset Distribution

For the Medical Devices & Instruments industry and Healthcare sector, DexCom's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where DexCom's Debt-to-Asset falls into.

DexCom Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

DexCom's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(21.1	+	2572.9)	/	6264.5
	=	0.41

DexCom's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(21.1	+	2572.9)	/	6264.5
	=	0.41

DexCom (NAS:DXCM) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

DexCom Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of DexCom's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

DexCom (DexCom) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » DexCom Inc (NAS:DXCM) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

DXCM:Mexico DC4:Germany DC4:Germany DC4:Germany DC4:Germany D1EX34:Brazil DXCM:Austria

Address

6340 Sequence Drive, San Diego, CA, USA, 92121

Website

https://www.dexcom.com

Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.

Executives

Sadie Stern	officer: Chief Human Resources Officer	6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Steven R Altman	director
Kevin R Sayer	director
Jereme M Sylvain	officer: SVP, Finance & CAO	6340 SEQUENCE DRIVE, SAN DIEGO X1 92121
Jacob Steven Leach	officer: SVP, Research & Development	6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Nicholas Augustinos	director	754 GRAND VIEW AVENUE, SAN FRANCISCO CA 94114
Micheal Jon Brown	officer: EVP, Chief Legal Officer	6340 SEQUENCE DR, SAN DIEGO CA 92121
Steven Robert Pacelli	officer: Vice President Legal Affairs	5555 OBERLIN DRIVE, SAN DIEGO CA 92121
Girish Naganathan	officer: EVP Chief Technology Officer	C/O DEXCOM, INC., 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Barry J. Regan	officer: EVP Operations	1023 CHERRY ROAD, MEMPHIS TN 38117
Bridgette P Heller	director	TECH DATA CORPORATION, 5350 TECH DATA DRIVE, CLEARWATER FL 33760
Matthew Vincent Dolan	officer: *	6340 SEQUENCE DR, SAN DIEGO CA 92121
Rimma Driscoll	director	C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY NJ 07054
Shelly Ramasamy Selvaraj	officer: SVP Information Technology	6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Paul R Flynn	officer: EVP, Global Revenue	6340 SEQUENCE DRIVE, SAN DIEGO CA 92121